Medical honey products manufacturer, Comvita, plans to challenge a legal decision which ruled one of its British patents invalid.
A British court last year revoked Comvita's patent for the wound care treatment, and ordered it to pay $835,000 to Brightwake Ltd for patent infringement.
Comvita says it's received legal advice showing the ruling is flawed on several grounds and plans to appeal the decision.
The cost of the appeal is expected to be less than $100,000 and the patent won't be revoked until an appeal is heard.
Meanwhile, Comvita says Derma Sciences, a US-based manufacturer, of which it owns 13%, has had positive results in a Phase two clinical trial for a new wound healing drug, DSC127.
The results show that the drug is up to three times more likely to heal diabetic foot ulcers than conventional treatment.
